XOMA Corporation (NASDAQ: XOMA) is excited to announce its acquisition of the commercial payment and milestone rights for IXINITY® [coagulation factor IX (recombinant)], a product marketed by Medexus Pharmaceuticals for the control and prevention of bleeding episodes and postoperative management in those with Hemophilia B. This acquisition from Aptevo Therapeutics marks an important milestone in XOMA’s journey to provide better healthcare options to those in need.
XOMA’s Chief Investment Officer, Brad Sitko, is excited to announce the addition of a new commercial payment stream that will benefit shareholders by helping to accelerate their royalty aggregation strategy. IXINITY has a reputable presence in the Hemophilia B treatment market, and there are strong prospects for label and geographic expansion in the near future.
XOMA has just sealed the deal with Aptevo, acquiring the full commercial payment stream and a portion of milestone rights pertaining to IXINITY for a total of $9.6 million. In addition, XOMA will receive mid-single digit percentage payments on all IXINITY sales from January 1, 2023 to the first quarter of 2035 and also be entitled to milestone payments starting in the second quarter of 2023.
About XOMA Corporation
XOMA is an innovative biotechnology royalty aggregator that helps biotech companies reach their goal of improving human health. It acquires the potential future economics of pre-commercial therapeutic candidates that have been licensed to pharmaceutical or biotech companies, providing the seller with non-dilutive, non-recourse funding. With a robust portfolio of over 70 assets, XOMA is the perfect partner for any biotech company looking to make an impact in the healthcare industry.